These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 28272224)
1. High expression of SALL4 and fascin, and loss of E-cadherin expression in undifferentiated/dedifferentiated carcinomas of the endometrium: An immunohistochemical and clinicopathologic study. Onder S; Taskin OC; Sen F; Topuz S; Kucucuk S; Sozen H; Ilhan R; Tuzlali S; Yavuz E Medicine (Baltimore); 2017 Mar; 96(10):e6248. PubMed ID: 28272224 [TBL] [Abstract][Full Text] [Related]
2. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Schlosshauer PW; Ellenson LH; Soslow RA Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748 [TBL] [Abstract][Full Text] [Related]
3. Fascin expression in undifferentiated and dedifferentiated endometrial carcinoma. Stewart CJ; Crook ML Hum Pathol; 2015 Oct; 46(10):1514-20. PubMed ID: 26239622 [TBL] [Abstract][Full Text] [Related]
4. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas. Moritz AW; Schlumbrecht MP; Nadji M; Pinto A Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050 [TBL] [Abstract][Full Text] [Related]
5. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas. Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164 [TBL] [Abstract][Full Text] [Related]
6. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Romero-Pérez L; López-García MÁ; Díaz-Martín J; Biscuola M; Castilla MÁ; Tafe LJ; Garg K; Oliva E; Matias-Guiu X; Soslow RA; Palacios J Mod Pathol; 2013 Nov; 26(11):1514-24. PubMed ID: 23743934 [TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases 2 and 9, E-cadherin, and beta-catenin expression in endometriosis, low-grade endometrial carcinoma and non-neoplastic eutopic endometrium. Shaco-Levy R; Sharabi S; Benharroch D; Piura B; Sion-Vardy N Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):226-32. PubMed ID: 18295959 [TBL] [Abstract][Full Text] [Related]
8. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. Huszar M; Pfeifer M; Schirmer U; Kiefel H; Konecny GE; Ben-Arie A; Edler L; Münch M; Müller-Holzner E; Jerabek-Klestil S; Abdel-Azim S; Marth C; Zeimet AG; Altevogt P; Fogel M J Pathol; 2010 Apr; 220(5):551-61. PubMed ID: 20077528 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of E-cadherin and beta-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear beta-catenin expression. Shih HC; Shiozawa T; Miyamoto T; Kashima H; Feng YZ; Kurai M; Konishi I Anticancer Res; 2004; 24(6):3843-50. PubMed ID: 15736420 [TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Holcomb K; Delatorre R; Pedemonte B; McLeod C; Anderson L; Chambers J Obstet Gynecol; 2002 Dec; 100(6):1290-5. PubMed ID: 12468176 [TBL] [Abstract][Full Text] [Related]
12. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142 [TBL] [Abstract][Full Text] [Related]
13. The Immunohistochemical Pattern of Epithelial-Mesenchymal Transition Markers In Endometrial Carcinoma. Rubeša-Mihaljević R; Babarović E; Vrdoljak-Mozetič D; Štemberger-Papić S; Klarić M; Krašević M; Jonjić N Appl Immunohistochem Mol Morphol; 2020; 28(5):339-346. PubMed ID: 30829665 [TBL] [Abstract][Full Text] [Related]
14. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. Yalta T; Atay L; Atalay F; Caydere M; Gonultas M; Ustun H J Int Med Res; 2009; 37(1):163-8. PubMed ID: 19215686 [TBL] [Abstract][Full Text] [Related]
15. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers. Ramalingam P; Masand RP; Euscher ED; Malpica A Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202 [TBL] [Abstract][Full Text] [Related]
17. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Alkushi A; Köbel M; Kalloger SE; Gilks CB Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148 [TBL] [Abstract][Full Text] [Related]